These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 28258694)

  • 1. Immunoregulatory functions of VISTA.
    Nowak EC; Lines JL; Varn FS; Deng J; Sarde A; Mabaera R; Kuta A; Le Mercier I; Cheng C; Noelle RJ
    Immunol Rev; 2017 Mar; 276(1):66-79. PubMed ID: 28258694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VISTA: A Novel Checkpoint for Cancer Immunotherapy.
    Gao Y; He Y; Tang Y; Chen ZS; Qu M
    Drug Discov Today; 2024 Jul; 29(7):104045. PubMed ID: 38797321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New checkpoints in cancer immunotherapy.
    Ni L; Dong C
    Immunol Rev; 2017 Mar; 276(1):52-65. PubMed ID: 28258699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expression and immunoregulation of immune checkpoint molecule VISTA in autoimmune diseases and cancers.
    Wang G; Tai R; Wu Y; Yang S; Wang J; Yu X; Lei L; Shan Z; Li N
    Cytokine Growth Factor Rev; 2020 Apr; 52():1-14. PubMed ID: 32057701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acidity changes immunology: a new VISTA pathway.
    Mahoney KM; Freeman GJ
    Nat Immunol; 2020 Jan; 21(1):13-16. PubMed ID: 31822869
    [No Abstract]   [Full Text] [Related]  

  • 6. VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity.
    ElTanbouly MA; Croteau W; Noelle RJ; Lines JL
    Semin Immunol; 2019 Apr; 42():101308. PubMed ID: 31604531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.
    Lines JL; Sempere LF; Broughton T; Wang L; Noelle R
    Cancer Immunol Res; 2014 Jun; 2(6):510-7. PubMed ID: 24894088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vista of the Future: Novel Immunotherapy Based on the Human V-Set Immunoregulatory Receptor for Digestive System Tumors.
    Chmiel P; Gęca K; Michalski A; Kłosińska M; Kaczyńska A; Polkowski WP; Pelc Z; Skórzewska M
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated.
    Mortezaee K; Majidpoor J; Najafi S
    Life Sci; 2022 Dec; 310():121083. PubMed ID: 36265568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
    Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M
    Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast Cancer.
    Xie X; Zhang J; Shi Z; Liu W; Hu X; Qie C; Chen W; Wang Y; Wang L; Jiang J; Liu J
    Front Immunol; 2020; 11():563044. PubMed ID: 33250890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.
    Janakiram M; Shah UA; Liu W; Zhao A; Schoenberg MP; Zang X
    Immunol Rev; 2017 Mar; 276(1):26-39. PubMed ID: 28258693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VISTA: Coming of age as a multi-lineage immune checkpoint.
    ElTanbouly MA; Schaafsma E; Noelle RJ; Lines JL
    Clin Exp Immunol; 2020 May; 200(2):120-130. PubMed ID: 31930484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VISTA: A promising target for overcoming immune evasion in gynecologic cancers.
    Liu S; Ji F; Ding Y; Ding B; Feng S; Brennick C; Lin H; Zhang T; Shen Y
    Int Immunopharmacol; 2024 Sep; 138():112655. PubMed ID: 38986302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses.
    Wang L; Rubinstein R; Lines JL; Wasiuk A; Ahonen C; Guo Y; Lu LF; Gondek D; Wang Y; Fava RA; Fiser A; Almo S; Noelle RJ
    J Exp Med; 2011 Mar; 208(3):577-92. PubMed ID: 21383057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VISTA Regulates the Development of Protective Antitumor Immunity.
    Le Mercier I; Chen W; Lines JL; Day M; Li J; Sergent P; Noelle RJ; Wang L
    Cancer Res; 2014 Apr; 74(7):1933-44. PubMed ID: 24691994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy.
    Huang X; Zhang X; Li E; Zhang G; Wang X; Tang T; Bai X; Liang T
    J Hematol Oncol; 2020 Jun; 13(1):83. PubMed ID: 32600443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy.
    Yuan L; Tatineni J; Mahoney KM; Freeman GJ
    Trends Immunol; 2021 Mar; 42(3):209-227. PubMed ID: 33495077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second- and third-generation drugs for immuno-oncology treatment-The more the better?
    Dempke WCM; Fenchel K; Uciechowski P; Dale SP
    Eur J Cancer; 2017 Mar; 74():55-72. PubMed ID: 28335888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. V-domain Ig suppressor of T cell activation (VISTA) inhibition is a new approach to cancer therapy: a Bibliometric study.
    Ait Boujmia OK
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Jun; 394(6):1057-1065. PubMed ID: 33616679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.